Erasca Q3 Loss Widens to $51.3M; $947.8M Cash Funds Pipeline Into 2027
ERAS has more than doubled off its 52-week low of $2.34.
Summary
Erasca posted a $51.3 million Q3 net loss and ended September with $947.8 million in cash and securities, enough to fund its RAS pipeline. The filing also discloses a new Revolution Medicines patent and trade-secret claim against ERAS-0015 alongside the existing securities and derivative suits.
Key Events · Earnings and Guidance · ERAS
-
Q3 Loss Widens on R&D Scale-Up
Net loss was $51.3 million for Q3 2026 versus $30.6 million a year earlier, driven by R&D of $47.2 million versus $22.5 million.
-
Cash Position Swells to $947.8M
Cash, cash equivalents and marketable securities reached $947.8 million at September 30, 2026, after the January 2026 offering raised $242.7 million net and the July 2026 offering raised $593.5 million net.
-
Revolution Medicines Alleges ERAS-0015 Infringement
An April 24, 2026 letter from RevMed's counsel claims ERAS-0015 infringes U.S. Patent No. 12,409,225 under the doctrine of equivalents and that a third party misappropriated RevMed trade secrets; Erasca says the claims are without merit.
-
Securities and Derivative Suits Advance
Lead plaintiffs were appointed October 20, 2026 in the securities class action, with Erasca's motion to dismiss due December 14, 2026; the derivative action was stayed October 7, 2026 pending that case.
Analysis · ERAS · Life Sciences
The balance sheet is the story here: $947.8 million in cash and securities after the January and July raises means Erasca can fund its ERAS-0015 registration-enabling trials and the ERAS-4001 Phase 1 without needing the market, even as Q3 burn rose with the RAS franchise scale-up. The offset is a heavier legal overhang — a securities class action with a December 14 motion-to-dismiss deadline, a stayed derivative suit, and a new Revolution Medicines letter alleging ERAS-0015 infringes its '225 Patent and was derived from its trade secrets. That patent claim is the one item that could change the thesis if it turns into litigation.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ERAS was trading at $15.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $2.34 to $24.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.